تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Abbott Laboratories's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $183.8B | |
|---|---|---|
| Revenue (ttm) | 48.2B | |
| Net income (ttm) | 4.7B | |
| EPS (ttm) | $2.69 | |
| Shares out | 1.7B | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 17.9x | |
| Dividend | $2.52 (2.45%) | |
| Volume | 4,052,721 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | +0.7% |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.33B | $24.61B | +1.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -1.4% |
| EBITDA | $12.16B | $11.89B | $10.61B | $10.83B | $11.55B | -1.3% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Recent company headlines from major financial publishers.
The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.
Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.3% | $99.9 | $106 | $115 | $127 | $146 |
| 6.3% | $87.9 | $91.7 | $96.6 | $103 | $111 |
| 7.3% | $79.6 | $82.1 | $86.7 | $88.8 | $93.4 |
| 8.3% | $73.4 | $75.2 | $77.2 | $79.6 | $82.5 |
| 9.3% | $68.7 | $69.9 | $71.4 | $73.0 | $74.9 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
